TAM-derived CCL7 Drives CRC Progression and Chemoresistance by Reprogramming Lipid Metabolism via the BATF3/USP22/DGAT2 Axis

Cancer Letters · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles